Fundraising Fox

Euclises

3 known investors

euclises.com ↗

Euclises develops Euclicoxibs, COX-2 inhibitor drug candidates designed to treat cancers driven by COX-2. The company focuses on oncology therapeutics with an emphasis on patient selection and dosing to maximize anti-cancer efficacy.

BiotechHealthtech

Investors · 3

iSelect FundSt. Louis · $250K – $2M
Cultivation Capitalreported · 2 sourcesSt. Louis · $100K – $3.5M
Missouri Technology CorporationreportedSt. Louis

In the news

Euclises Pharmaceuticals Receives Notice Of Patent Allowance From European Patent Office For New Class Of Compounds For Treatment Of Cancer, Pain And Inflammation - BioSpacebiospace.com · Dec 2015Euclises Pharmaceuticals Co-Founder Named 2015 Power Medicine Maker - BioSpacebiospace.com · May 2015Euclises Pharmaceuticals Completes Nearly $2M Series A Funding - FinSMEsfinsmes.com · Apr 2015Euclises Announces Development Agreement with GIBH | VentureBeatventurebeat.com · Dec 2014Euclises Announces Series A Financing | VentureBeatventurebeat.com · Sep 2014Euclises Pharmaceuticals Closes $1.3M Series A Financing - FinSMEsfinsmes.com · Sep 2014

Frequently asked questions

What does Euclises do?
Euclises develops Euclicoxibs, COX-2 inhibitor drug candidates designed to treat cancers driven by COX-2. The company focuses on oncology therapeutics with an emphasis on patient selection and dosing to maximize anti-cancer efficacy.
Who are Euclises's investors?
Euclises's investors include iSelect Fund, Cultivation Capital, Missouri Technology Corporation.